Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)

by R. Bartsch, D. Lüftner, M. Balic, G. Rinnerthaler, C. Jackisch, V. Müller, M. Schmidt, N. Harbeck
Published 2021-04-01

Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

by D. Lüftner, H. Tesch, M. Schmidt, A. Hartkopf, S. Streicher, A. Resch, L. Genovese, C. Rosé, R. Valenti, N. Harbeck
Published 2021-04-01

Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective – prospective observational study –...

by H. Hoefeler, I. Duran, G. Hechmati, C. Garzon Rodriguez, D. Lüftner, J. Ashcroft, A. Bahl, C. Atchison, R. Wei, E. Thomas, V. Lorusso
Published 2014-05-01